share_log

HC Wainwright & Co. Initiates Coverage On Acurx Pharmaceuticals With Buy Rating, Announces Price Target of $14

HC Wainwright & Co. Initiates Coverage On Acurx Pharmaceuticals With Buy Rating, Announces Price Target of $14

HC Wainwright & Co.以买入评级开始对Acurx Pharmicals进行报道,宣布目标价为14美元
Benzinga Real-time News ·  2022/12/19 06:11

HC Wainwright & Co. analyst Ed Arce initiates coverage on Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy rating and announces Price Target of $14.

HC Wainwright&Co.分析师Ed Arce以买入评级启动对Acurx制药(纳斯达克:ACXP)的报道,并宣布目标价为14美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发